Immuneering Shares Are Trading Lower After the Company Announced Topline Result From the Ongoing Phase 1 Portion of Its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced RAS-mutant Solid Tumors
Immuneering的股价走低,此前该公司公布了正在进行的针对晚期 RAS-突变实体瘤的 IMM-1-104 1/2a 期临床试验 1 期的总体结果